Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Dr. Stefanovic on the Emergence of Umbralisib in MZL and Follicular Lymphoma

November 18th 2021

Alexandra Stefanovic, MD, discusses the emergence of umbralisib in marginal zone lymphoma and follicular lymphoma.

FDA Grants Fast Track Status to SETD2 Inhibitor EZM0414 for Relapsed/Refractory DLBCL

November 5th 2021

The FDA granted a fast track designation to EZM0414, a first-in-class, oral SETD2 inhibitor, for use as a potential therapeutic option in adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Devimistat Granted Orphan Drug Designation in Europe for Relapsed/Refractory Burkitt Lymphoma

November 4th 2021

The European Medicines Agency granted an orphan drug designation to devimistat for the treatment of patients with relapsed or refractory Burkitt lymphoma. The novel compound targets mitochondria in tumor cells.

Dr. Foss on Pursuing New Therapeutic Options in T-Cell Non-Hodgkin Lymphoma

November 3rd 2021

Francine Foss, MD, discusses pursing new therapeutic options for the treatment of patients with T-cell non-Hodgkin lymphoma.

FDA Approval Sought for Parsaclisib in 3 Types of Relapsed/Refractory Non-Hodgkin Lymphoma

November 1st 2021

The FDA has accepted a new drug application for the PI3Kδ inhibitor parsaclisib for use in the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.

FDA Grants Priority Review to Tisagenlecleucel for Relapsed/Refractory Follicular Lymphoma

October 28th 2021

The FDA has granted a priority review to tisagenlecleucel for use in adult patients with relapsed or refractory follicular lymphoma.

CAR T-cell Therapy CTX110 Shows Early Promise for Relapsed/Refractory CD19+ B-cell Malignancies

October 13th 2021

The allogeneic CD19-targeted CAR T-cell therapy CTX110 was found to elicit encouraging responses with favorable tolerability in patients with relapsed or refractory B-cell malignancies, according to data from the phase 1 CARBON trial.

Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

October 4th 2021

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Epcoritamab Shows Robust Antitumor Activity, Acceptable Safety in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

September 30th 2021

Epcoritamab had a manageable toxicity profile when subcutaneously administered to patients with relapsed/refractory B-cell non-Hodgkin lymphoma and was found to elicit encouraging responses in those who were heavily pretreated.

Dr. Herrera on the Potential for Frontline CAR T-Cell Therapy in DLBCL

September 20th 2021

Alex Herrera, MD, discusses the potential for CAR T-cell therapy in earlier lines of treatment for patients with diffuse large B-cell lymphoma.

Zanubrutinib Approaches EU Approval for Waldenström Macroglobulinemia

September 17th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding the use of zanubrutinib in adult patients with Waldenström macroglobulinemia who have previously received at least 1 therapy or in the frontline treatment of patients who are not eligible for chemoimmunotherapy.

FDA Approves Zanubrutinib for Relapsed or Refractory Marginal Zone Lymphoma

September 15th 2021

The FDA has granted an accelerated approval to zanubrutinib for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least 1 anti–CD20-based regimen.

Racial, Social Disparities Linked With T-Cell Lymphoma Outcomes

September 11th 2021

Existing racial and socioeconomic disparities among patients with T-cell non-Hodgkin lymphoma continue to lead to obstacles with access for newly available treatment options.

CAR T-Cell Therapies Show Promise Across Indolent Lymphomas

September 10th 2021

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

Tafasitamab Plus Lenalidomide Approved in Europe for Relapsed/Refractory DLBCL

August 27th 2021

The European Commission has granted a conditional marketing authorization to tafasitamab plus lenalidomide followed by single-agent tafasitamab for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.

Ibrutinib Shows Continued Activity in Relapsed, Variant-Type Hairy Cell Leukemia

August 27th 2021

Ibrutinib demonstrated encouraging clinical responses in patients with variant-type, high-risk hairy cell leukemia.

Next Steps With Loncastuximab Tesirine in LBCL Involve Exploring Novel Combo Regimens

August 25th 2021

Paolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine in large B-cell lymphoma, results from the phase 2 LOTIS-2 trial, and future research directions with the agent.

Mosunetuzumab Elicits High, Durable Responses in Multiply Relapsed Follicular Lymphoma

August 24th 2021

Fixed-duration treatment with mosunetuzumab elicited encouraging responses with acceptable safety when used in patients with multiply relapsed follicular lymphoma.

Off-the-Shelf NK Cell Products FT596 and FT516 Show Early Promise in B-cell Lymphoma

August 23rd 2021

Regimens that included the off-the-shelf, induced pluripotent stem cell–derived natural killer cell products FT596 and FT516 were found to elicit encouraging responses with favorable tolerability when used in patients with B-cell lymphoma.

Future of Care for PCNSL Relies on Adapting Personalized Approaches

August 23rd 2021

Primary central nervous system lymphoma is a rare and aggressive variant of extranodal non-Hodgkin lymphoma that occurs in the brain, spinal cord, cerebrospinal fluid, or eyes in the absence of systemic disease.